| Trial ID # | NCT05918445 |
| Phase | I/II |
| Drug Class | Immunotherapy: Bispecifics/PD-L1, VEGF |
| Drug Name | BNT327 |
| Alternate Drug Names | anti-PD-L1/anti-VEGF-A bispecific antibody PM8002, PM8002 |
| Drugs in Trial | BNT327 |
| Eligible Participant | Platinum resistant ovarian cancer (0-1 prior therapies for platinum resistant recurrence) |
| Patients Enrolled | 39 |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, DCR, DoR, PFS, OS, evaluated per RECIST |
| Efficacy | ORR: 20.6% (7PR, n=34) |
| Clinically Significant Adverse Events | Serious AE: |
| Conclusion | BNT327 (PM8002) shows promising anti-tumor activity in previously treated patients with Pt-R OC |
| Reference | Wu L et al. Efficacy and safety of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with solid tumors: Clinical data from advanced cervical cancer and platinum-resistant recurrent ovarian cancer cohorts. J Clin Oncol 42, 2024 (suppl 16; abstr 5524) Wu L et al. Poster |
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.